Protagonist Therapeutics Inc (NASDAQ: PTGX) is -5.85% lower on its value in year-to-date trading and has touched a low of $24.22 and a high of $48.89 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PTGX stock was last observed hovering at around $36.15 in the last trading session, with the day’s gains setting it 0.19%.
Currently trading at $36.34, the stock is -3.57% and -4.96% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.93 million and changing 0.53% at the moment leaves the stock -7.78% off its SMA200. PTGX registered 23.06% gain for a year compared to 6-month loss of -12.64%.
The stock witnessed a -4.34% gain in the last 1 month and extending the period to 3 months gives it a -21.78%, and is -5.59% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.85% over the week and 4.14% over the month.
Protagonist Therapeutics Inc (PTGX) has around 126 employees, a market worth around $2.23B and $434.43M in sales. Current P/E ratio is 8.64. Profit margin for the company is 63.34%. Distance from 52-week low is 50.04% and -25.67% from its 52-week high. The company has generated returns on investments over the last 12 months (40.14%).
with sales reaching $32.59M over the same period.The EPS is expected to shrink by -133.00% this year, but quarterly earnings will post -78.43% year-over-year. Quarterly sales are estimated to shrink -87.22% in year-over-year returns.
The shares outstanding are 61.04M, and float is at 57.79M with Short Float at 7.30%.
The top institutional shareholder in the company is FARALLON CAPITAL MANAGEMENT LLC with over 5.84 million shares valued at $202.38 million. The investor’s holdings represent 9.5274 of the PTGX Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.76 million shares valued at $199.52 million to account for 9.3925 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 5.29 million shares representing 8.6231 and valued at over $183.17 million, while BVF INC/IL holds 5.4144 of the shares totaling 3.32 million with a market value of $115.01 million.
Protagonist Therapeutics Inc (PTGX) Insider Activity
The most recent transaction is an insider sale by PATEL DINESH V PH D, the company’s President and CEO. SEC filings show that PATEL DINESH V PH D sold 5,359 shares of the company’s common stock on Feb 19 ’25 at a price of $38.18 per share for a total of $0.2 million. Following the sale, the insider now owns 0.54 million shares.
Protagonist Therapeutics Inc disclosed in a document filed with the SEC on Nov 27 ’24 that MOLINA ARTURO MD (Chief Medical Officer) sold a total of 26,000 shares of the company’s common stock. The trade occurred on Nov 27 ’24 and was made at $44.70 per share for $1.16 million. Following the transaction, the insider now directly holds 46444.0 shares of the PTGX stock.
Still, SEC filings show that on Nov 26 ’24, MOLINA ARTURO MD (Chief Medical Officer) disposed off 5,529 shares at an average price of $45.60 for $0.25 million. The insider now directly holds 46,444 shares of Protagonist Therapeutics Inc (PTGX).
